Project Grant K08HL177151
Award Date 8/15/25
Completion Date 5/31/30
Dollars Obligated $171K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
- The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, awarded a $1,127,798 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). This 7-year grant, effective February 1, 2025, will support research to understand the role of macrophages in preserving cardiovascular health, illuminating their contributions to cardiovascular disease, and...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $170,640 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research on the role of the airway hillock cell type in airway barrier function and regeneration. The award period runs from September 15, 2025 to August 31, 2030. The research aims to define the mechanisms by which the hillock cell resists injury and...
- This $165,353 Project Grant was awarded on September 25, 2025 by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The grant funding will support research to define the association between severe obesity and regional lung perfusion, as well as test the effect of severe obesity on pulmonary vasoreactivity in patients with acute hypoxemic respiratory failure....
- This $453,750 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), as part of the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), with an award date of June 17, 2025 and an ultimate completion date of May 31, 2027. The grant supports research to define novel mechanisms of communication between airway epithelial cells and intraepithelial airway macrophages, using an innovative high-throughput airway organoid screening...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $144,989 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop, train, and test deep generative models using computed tomography (CT) images to predict lung injury progression and treatment responses in patients with acute respiratory distress syndrome (ARDS). The goal is to leverage artificial intelligence and image...
- The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, awarded a $667,776 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The 5-year grant, with a start date of June 15, 2025 and an end date of April 30, 2030, aims to generate clinical evidence on the use of antenatal late preterm steroids (ALPS) to reduce preventable neonatal...
- The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), received a $712,268 Project Grant award from the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) to establish the Uganda Lung Health Study. This 5-year longitudinal study aims to investigate the intersection of HIV, sex, and chronic obstructive pulmonary disease (COPD) risk among 800 adolescents and adults in Sub-Saharan Africa, a region expected to...
- The Project Grant award of $759,658 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research at The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop and validate a mechanomicroscopy imaging platform for the transbronchial assessment of pulmonary artery pressure and arterial smooth muscle thickening in patients with pulmonary hypertension due to lung disease. The key products and services to be...
- This $136,050 Project Grant was awarded on June 30, 2025 by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, to Tufts University School of Medicine. The grant supports research to characterize lung resident B1 cells and their impact on lung homeostasis during development. The research aims to investigate the functional role of B1 cells in developing lungs and their contribution to maintaining lung homeostasis, which...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $594,583 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Children's Hospital of Philadelphia (CHOP) Research Institute. The grant supports research to investigate the mechanisms regulating the development, expansion, and decline of neonatal lung myofibroblasts and their role in alveologenesis. Key objectives include utilizing a novel murine model to study myofibroblast lineage, characterize...